Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Pharmaceutical 89

Pharmaceutical

Pharma happenings for Urovant's vibegron Genmab and Polyphor

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors in mice Several viruses have a natural ability to eliminate cancer; however translating them into treatments has proven difficult, partly due to the immune system tends to kill them before they can reach cancer cells. Researchers from Emory and Case Western Reserve state they have got a method to succeed that challenge with a specially engineered virus. The team took human adenovirus and re-engineered it so the immune system cannot capture it and sent to the liver for destruction, in mouse models of metastatic lung cancer, the virus prolonged survival. About 35% of the animals were ...

Explore More...

Default Blog Image

NF-κB Inhibitors- A Promising Future

transthyretin amyloidosis

Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates

transthyretin amyloidosis

Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation

parkinson's

Parkinson’s and tuberculosis shares a common protein that could provide better drugs for both

Notizia

Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating

Entasis

Business Cocktail

COMMON COLD

Potential cure for Common cold

Hematopoietic stem cells

Hematopoietic Stem Cell Transplantation

Takeda buys Shire in a deal worth USD 62 billion

transthyretin amyloidosis

Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod

Default Blog Image

Horizon Discovery declines Abcam’s USD 367 million takeover bid

transthyretin amyloidosis

Notizia

transthyretin amyloidosis

Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients

Signal Transducer and Activator of Transcription

STAT INHIBITORS- Highly active Pipeline

Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.

Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment

Default Blog Image

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly